The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
Susan Halabi
Research Funding - Sanofi
Chen-Yen Lin
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose
Andrew J. Armstrong
Consultant or Advisory Role - Bayer
Research Funding - Janssen Pharmaceutical ; Medivation; Sanofi
Other Remuneration - Sanofi
Ellen B. Kaplan
No relevant relationships to disclose
Daniel Peter Petrylak
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi
Cora N. Sternberg
Consultant or Advisory Role - Sanofi
Liji Shen
Employment or Leadership Position - Sanofi
Stephane Oudard
Honoraria - Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi
Johann Sebastian De Bono
Honoraria - Sanofi
Research Funding - Sanofi
A. Oliver Sartor
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi